vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $9.3M, roughly 1.0× STRATA Skin Sciences, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs 0.6%, a 26.7% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs -3.0%). ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $-551.0K). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs 17.3%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
ECBK vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $9.3M |
| Net Profit | $2.6M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 36.7% | 5.3% |
| Net Margin | 27.3% | 0.6% |
| Revenue YoY | 33.8% | -3.0% |
| Net Profit YoY | 79.5% | 101.3% |
| EPS (diluted) | $0.32 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $9.3M | ||
| Q3 25 | $8.8M | $6.9M | ||
| Q2 25 | $8.0M | $7.7M | ||
| Q1 25 | $6.9M | $6.8M | ||
| Q4 24 | $7.1M | $9.6M | ||
| Q3 24 | $6.6M | $8.8M | ||
| Q2 24 | $6.3M | $8.4M | ||
| Q1 24 | $6.2M | $6.8M |
| Q4 25 | $2.6M | $58.0K | ||
| Q3 25 | $2.4M | $-1.6M | ||
| Q2 25 | $1.4M | $-2.6M | ||
| Q1 25 | $1.3M | $-2.1M | ||
| Q4 24 | $1.4M | $-4.6M | ||
| Q3 24 | $1.1M | $-2.1M | ||
| Q2 24 | $791.0K | $-91.0K | ||
| Q1 24 | $621.0K | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 36.7% | 5.3% | ||
| Q3 25 | 37.0% | -16.9% | ||
| Q2 25 | 23.9% | -30.1% | ||
| Q1 25 | 24.9% | -25.0% | ||
| Q4 24 | 27.3% | -44.7% | ||
| Q3 24 | 23.3% | -18.2% | ||
| Q2 24 | 16.9% | -5.7% | ||
| Q1 24 | 13.4% | -42.7% |
| Q4 25 | 27.3% | 0.6% | ||
| Q3 25 | 27.7% | -23.4% | ||
| Q2 25 | 18.0% | -33.6% | ||
| Q1 25 | 18.7% | -31.2% | ||
| Q4 24 | 20.3% | -47.6% | ||
| Q3 24 | 17.2% | -23.6% | ||
| Q2 24 | 12.6% | -1.1% | ||
| Q1 24 | 10.0% | -49.8% |
| Q4 25 | $0.32 | $0.14 | ||
| Q3 25 | $0.29 | $-0.36 | ||
| Q2 25 | $0.17 | $-0.62 | ||
| Q1 25 | $0.16 | $-0.51 | ||
| Q4 24 | $0.18 | $-2.01 | ||
| Q3 24 | $0.14 | $-0.51 | ||
| Q2 24 | $0.09 | $-0.03 | ||
| Q1 24 | $0.07 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $171.9M | $2.9M |
| Total Assets | $1.6B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $7.9M | ||
| Q3 25 | $201.9M | $7.1M | ||
| Q2 25 | $191.0M | $6.0M | ||
| Q1 25 | $143.7M | $6.5M | ||
| Q4 24 | $309.4M | $7.3M | ||
| Q3 24 | $114.8M | $7.1M | ||
| Q2 24 | $108.7M | $5.5M | ||
| Q1 24 | $109.8M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $171.9M | $2.9M | ||
| Q3 25 | $169.3M | $1.3M | ||
| Q2 25 | $168.3M | $532.0K | ||
| Q1 25 | $168.6M | $3.0M | ||
| Q4 24 | $168.3M | $5.0M | ||
| Q3 24 | $166.0M | $9.4M | ||
| Q2 24 | $166.5M | $9.5M | ||
| Q1 24 | $165.8M | $9.4M |
| Q4 25 | $1.6B | $30.5M | ||
| Q3 25 | $1.6B | $30.7M | ||
| Q2 25 | $1.5B | $29.5M | ||
| Q1 25 | $1.5B | $33.0M | ||
| Q4 24 | $1.4B | $34.9M | ||
| Q3 24 | $1.4B | $39.4M | ||
| Q2 24 | $1.3B | $38.8M | ||
| Q1 24 | $1.3B | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-239.0K |
| Free Cash FlowOCF − Capex | $9.0M | $-551.0K |
| FCF MarginFCF / Revenue | 94.7% | -5.9% |
| Capex IntensityCapex / Revenue | 2.2% | 3.4% |
| Cash ConversionOCF / Net Profit | 3.55× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-239.0K | ||
| Q3 25 | $4.0M | $-64.0K | ||
| Q2 25 | $1.9M | $-1.9M | ||
| Q1 25 | $-631.0K | $-550.0K | ||
| Q4 24 | $6.2M | $703.0K | ||
| Q3 24 | $861.0K | $-302.0K | ||
| Q2 24 | $1.4M | $591.0K | ||
| Q1 24 | $-429.0K | $-804.0K |
| Q4 25 | $9.0M | $-551.0K | ||
| Q3 25 | $4.0M | $-1.1M | ||
| Q2 25 | $1.8M | $-2.0M | ||
| Q1 25 | $-649.0K | $-749.0K | ||
| Q4 24 | $6.2M | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | $1.3M | $246.0K | ||
| Q1 24 | $-449.0K | $-1.5M |
| Q4 25 | 94.7% | -5.9% | ||
| Q3 25 | 44.9% | -15.6% | ||
| Q2 25 | 23.0% | -26.1% | ||
| Q1 25 | -9.4% | -11.0% | ||
| Q4 24 | 86.8% | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | 21.4% | 2.9% | ||
| Q1 24 | -7.2% | -22.6% |
| Q4 25 | 2.2% | 3.4% | ||
| Q3 25 | 0.8% | 14.7% | ||
| Q2 25 | 0.6% | 0.8% | ||
| Q1 25 | 0.3% | 2.9% | ||
| Q4 24 | 0.8% | 5.3% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.6% | 4.1% | ||
| Q1 24 | 0.3% | 10.7% |
| Q4 25 | 3.55× | -4.12× | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECBK
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
